Journal Mobile Options
Table of Contents
Vol. 60, No. 2, 2009
Issue release date: October 2009

Reduced Response to Reward in Smokers and Cannabis Users

Martin-Soelch C. · Kobel M. · Stoecklin M. · Michael T. · Weber S. · Krebs B. · Opwis K.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Cannabis is one of the most commonly used illicit drugs. Reduced neural and behavioral reactions to reward have been demonstrated in other forms of addiction, as expressed by reduced mood reactivity and lack of striatal activation to rewards, but this effect has not yet been investigated in cannabis users. Methods: We hypothesized that cannabis users and tobacco smokers would evidence lower positive mood ratings in rewarded conditions than control participants and that this reduction would be greater in cannabis users than in smokers. We examined the influence of reward on mood and performance in a group of regular cannabis users, a group of tobacco smokers and a group of nonsmokers while they performed a spatial recognition task with delayed response that incorporated 3 levels of difficulty. Correct responses were either not reinforced or reinforced with money. We measured the accuracy of reactions, reaction times and mood ratings throughout the trials. Results: Cannabis users rated their mood as significantly worse than the smokers and nonsmokers during the easiest level of the rewarded condition. A significant positive correlation between mood ratings and monetary reward was found in the nonsmokers but not in the cannabis users and smokers. The groups did not differ with regard to task performance. Conclusions: Our results suggest that regular cannabis use affects certain aspects of motivation and that both tobacco smoking and cannabis use lead to similar motivational changes. However, the use of cannabis seems to affect motivation in a stronger way than does tobacco smoking alone.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Raphael B, Wooding S, Stevens G, Connor J: Comorbidity: cannabis and complexity. J Psychiatr Pract 2005;11:161–176.
  2. Kalant H: Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:849–863.
  3. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller MM, Christiansen K, McRee B, Vendetti J: Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002;287:1123–1131.
  4. Whitlow CT, Liguori A, Livengood LB, Hart SL, Mussat-Whitlow BJ, Lamborn CM, Laurienti PJ, Porrino LJ: Long-term heavy marijuana users make costly decisions on a gambling task. Drug Alcohol Depend 2004;76:107–111.
  5. Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O: Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002;43:857–867.
  6. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE: Teen drug use down but progress halts among youngest teens. Ann Arbor, University of Michigan News and Information Services. http://www.monitoringthefuture.org/pressreleases/05drugpr_complete.pdf.
  7. Mathers M, Toumbourou JW, Catalano RF, Williams J, Patton GC: Consequences of youth tobacco use: a review of prospective behavioural studies. Addiction 2006;101:948–958.
  8. Agrawal A, Lynskey MT, Pergadia ML, Bucholz KK, Heath AC, Martin NG, Madden PA: Early cannabis use and DSM-IV nicotine dependence: a twin study. Addiction 2008;103:1896–1904.
  9. Agrawal A, Madden PA, Bucholz KK, Heath AC, Lynskey MT: Transitions to regular smoking and to nicotine dependence in women using cannabis. Drug Alcohol Depend 2008;95:107–114.
  10. Benwell ME, Balfour DJ: The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 1992;105:849–856.
  11. Chen JP, Paredes W, Lowinson JH, Gardner EL: Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci Lett 1991;129:136–180.
  12. Imperato A, Mulas A, Di Chiara G: Nicotine preferentially stimulates dopamine in the limbic system of freely moving rats. Eur J Pharmacol 1986;132:337–338.
  13. Nisell M, Nomikos GG, Svensson TH: Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994;16:36–44.
  14. Tanda G, Pontieri FE, Di Chiara G: Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;276:2048–2050.
  15. Taylor DA, Sitaram BR, Elliot-Baker S: Effect of d-9-tetrahydrocannabinol on release of dopamine in the corpus striatum of the rat; in Chesher G, Consroe P, Musty R (eds): Marijuana: An International Research Report. Canberra, Australian Government Publishing Service, 1988, pp 405–408.
  16. Di Chiara G: The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 1995;38:95–137.
  17. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, Acquas E, Carboni E, Valentini V, Lecca D: Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004;47:227–241.
  18. Koob G, LeMoal M: Drug abuse: hedonic homeostatic dysregulation. Science 1997;278:52–58.
  19. Martin-Soelch C, Leenders KL, Chevalley AF, Missimer J, Künig G, Magyar S, Mino A, Schultz W: Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies. Brain Res Rev 2001;36:139–149.
  20. Delgado MR, Nystrom LE, Fissell C, Noll DC, Fiez JA: Tracking the hemodynamic responses to reward and punishment in the striatum. J Neurophysiol 2000;84:3072–3077.
  21. Elliott R, Newman JL, Longe OA, Deakin JF: Differential response patterns in the striatum and orbitofrontal cortex to financial reward in humans: a parametric functional magnetic resonance imaging study. J Neurosci 2003;23:303–307.
  22. Hikosaka K, Watanabe M: Delay activity of orbital and lateral prefrontal neurons of the monkey varying with different rewards. Cereb Cortex 2000;10:263–271.
  23. Knutson B, Fong GW, Adams CM, Varner JL, Hommer D: Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport 2001;12:3683–3687.
  24. O’Doherty JP, Kringelbach ML, Rolls ET, Hornak J, Andrew C: Abstract reward and punishment representations in the human orbitofrontal cortex. Nat Neurosci 2001;4:12.
  25. Parkinson J, Crofts H, McGuigan M, Tomic D, Everitt B, Roberts A: The role of the primate amygdala in conditioned reinforcement. J Neurosci 2001;21:7770–7780.
  26. Schultz W: Behavioral theories and the neurophysiology of reward. Annu Rev Psychol 2006;57:87–115.
  27. Carlezon WA, Wise RA: Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci 1996;16:3112–3122.
  28. Gardner EL: Brain reward mechanisms; in Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds): Substance Abuse: A Comprehensive Textbook, ed 3. Baltimore, Williams & Wilkins, 1997, pp 51–85.
  29. Gardner EL: Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 2005;81:263–284.
  30. Chen J, Paredes W, Li J, Smith D, Lowinson J, Gardner EL: Δ9-Tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 1990;102:156–162.
  31. Gardner EL, Paredes W, Smith D, Zukin RS: Facilitation of brain stimulation reward by Δ9-tetrahydrocannabinol is mediated by an endogenous opioid mechanism. Adv Biosci 1989;75:671–674.
  32. Bloom AS, Dewey WL: A comparison of some pharmacological actions of morphine and d9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl) 1978;57:243–248.
  33. Braida D, Pozzi M, Parolaro D, Sala M: Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol 2001;413:227–234.
  34. Justinova Z, Tanda G, Munzar P, Goldberg SR: The opioid antagonist naltrexone reduces the reinforcing effects of Δ9-tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl) 2004;173:186–194.
  35. Martin-Soelch C, Magyar S, Künig G, Missimer J, Schultz W, Leenders KL: Changes in brain activation associated with reward processing in smokers and nonsmokers: a positron emission tomography study. Exp Brain Res 2001;139:278–386.
  36. Martin-Soelch C, Missimer J, Leenders K, Schultz W: Neural activity related to the processing of increasing monetary reward in smokers and nonsmokers. Eur J Neurosci 2003;18:680–688.
  37. Martin-Soelch C, Chevalley AF, Künig G, Missimer J, Magyar S, Mino A, Schultz W, Leenders KL: Changes in reward-induced brain activation in opiate addicts. Eur J Neurosci 2001;14:1360–1368.
  38. Glahn DC, Kim J, Cohen MS, Poutanen VP, Therman S, Bava S, Van Erp TG, Manninen M, Huttunen M, Lonnqvist J, Standertskjold-Nordenstam CG, Cannon TD: Maintenance and manipulation of spatial working memory: dissociations in the prefrontal cortex. Neuroimage 2002;17:201–213.
  39. Jenkins GD, Mitra A, Gupta N, Shaw JD: Are financial incentives related to performance? A meta-analytic review of empirical research. J Appl Psychol 1998;83:777–787.
  40. Camerer CF, Hogarth RM: The effects of financial incentives in experiments: a review and capital-labor-production framework. J Risk Uncertain 1999;19:7–42.

    External Resources

  41. Martin-Soelch C: Reward and Dependence. Bern, Peter Lang, 2002.
  42. Rao S, Hammeke TA, McQuillen MP, Kathri BO, Lloyd D: Memory disturbance in chronic progressive multiple sclerosis. Arch Neurol 1984;41:625–631.
  43. Brickenkamp R: Test d2. Aufmerksamkeits-Belastungs-Test. Göttingen, Hogrefe, 1981.
  44. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
  45. WHO: ICD-10 Symptom-Checkliste für psychische Störungen. Bern, Huber, 1995.
  46. Fagerström K-O: Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978;3:235–241.
  47. Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65–70.

    External Resources

  48. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA: Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001;49:81–96.
  49. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M: Imaging human mesolimbic dopamine transmission with positron emission tomography. II. Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003;23:285–300.
  50. Koob G: Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 2009;56:18–31.
  51. Melis M, Spiga S, Diana M: The dopamine hypothesis of drug addiction: hypodopaminergic state. Int Rev Neurobiol 2005;63:101–154.
  52. Heimer L, Alheid GF: Piecing together the puzzle of basal forebrain anatomy. Adv Exp Med Biol 1991;295:1–42.
  53. Heimer L, Alheid GF, Zahm DS: Basal forebrain organization: an anatomical framework for motor aspects of drive and motivation; in Kalivas PW, Barnes CD (eds): Limbic Motor Circuits and Neuropsychiatry. Boca Raton, CRC, 1993, pp 1–43.
  54. Koob G: Allostatic view of motivation: implications for psychopathology; in Bevins RA, Bardo MT (eds): Motivational Factors in the Etiology of Drug Abuse. Nebraska Symposium on Motivation. Lincoln, University of Nebraska Press, 2004, vol 50, pp 1–18.
  55. Smith R, Aston-Jones G: Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct 2008;213:43–61.
  56. Viveros MP, Marco EM, Llorente R, Lopez-Gallardo M: Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007;2007:52908.
  57. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O’Carrol C, Atakan Z, Zuardi AW, McGuire PK: Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009;66:95–105.
  58. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H: Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008;28:2313–2319.
  59. Dorard G, Berthoz S, Phan O, Corcos M, Bungener C: Affect dysregulation in cannabis abusers: a study in adolescents and young adults. Eur Child Adolesc Psychiatry 2008;17:274–282.
  60. Osborne GB, Fogel C: Understanding the motivations for recreational marijuana use among adult Canadians. Subst Use Misuse 2008;43:539–572, discussion 573–579, 585–587.
  61. Schaub M, Fanghaenel K, Stohler R: Reasons for cannabis use: patients with schizophrenia versus matched healthy controls. Aust NZ J Psychiatry 2008;42:1060–1065.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50